中国P站

Microbiota-driven prevention; Gut microbiome; Oncogenic risk; Dysbiosis; Probiotics; Prebiotics; Short-chain fatty acids; Inflammation control; Microbial modulation; Colorectal cancer; Microbiome balance; Dietary intervention; Fecal microbiota transplantation; Cancer risk reduction; Host-microbe interaction

Introduction

In recent years, the human microbiome—particularly the gut microbiota—has emerged as a crucial regulator of immune function, metabolic activity, and host-pathogen interactions. This microbial community, composed of trillions of bacteria, fungi, viruses, and archaea, influences multiple aspects of health and disease. An area gaining increasing attention is the role of the microbiome in cancer prevention [1-5]. Evidence suggests that microbial imbalances, or dysbiosis, can contribute to oncogenesis by promoting inflammation, producing carcinogenic metabolites, or weakening immune surveillance. Conversely, maintaining or restoring a healthy microbiome may reduce oncogenic risk. The concept of microbiota-driven cancer prevention refers to intentional modulation of microbial populations through interventions such as diet, probiotics, prebiotics, and fecal microbiota transplantation (FMT) to decrease the likelihood of cancer development. This emerging approach aims to shift prevention strategies from generalized recommendations to targeted, microbiome-informed interventions that address individual risk profiles [6-10].

Discussion

The gut microbiota plays a central role in maintaining mucosal homeostasis and modulating host immunity. Beneficial microbial species promote anti-inflammatory pathways, enhance barrier function, and produce metabolites such as short-chain fatty acids (SCFAs), which exert protective effects against cancer. SCFAs like butyrate not only nourish colonocytes but also regulate gene expression, inhibit histone deacetylases (HDACs), and promote apoptosis in abnormal cells.

In contrast, dysbiosis—often caused by poor diet, antibiotic overuse, or stress—can result in an overgrowth of harmful bacteria, leading to chronic inflammation, oxidative stress, and increased production of genotoxins such as colibactin and secondary bile acids. These conditions create a microenvironment conducive to DNA damage, immune evasion, and tumor progression. Notably, specific bacterial strains such as Fusobacterium nucleatum, Escherichia coli, and enterotoxigenic Bacteroides fragilis have been implicated in colorectal cancer development.

Microbiota modulation strategies are being explored as preventive tools to restore balance and suppress tumor-promoting mechanisms. Probiotics—live beneficial microorganisms—have demonstrated potential to reduce inflammation, enhance mucosal immunity, and compete with pathogenic bacteria. Strains like Lactobacillus rhamnosus and Bifidobacterium longum have shown promise in reducing precancerous lesions and restoring microbial diversity.

Prebiotics, typically non-digestible dietary fibers such as inulin or fructooligosaccharides, selectively stimulate the growth of beneficial bacteria. These compounds improve gut ecology and increase SCFA production, indirectly contributing to reduced cancer risk. In clinical studies, prebiotic intake has been associated with decreased biomarkers of inflammation and carcinogenesis in the colon.

Another advanced intervention is Fecal Microbiota Transplantation (FMT), where microbiota from a healthy donor are introduced into a patient’s gut. While still experimental in cancer prevention, FMT has proven effective in restoring microbial diversity and is being studied for its role in reversing dysbiosis-linked precancerous conditions.

Dietary modification remains a cornerstone in microbiota-driven prevention. Diets rich in plant-based foods, fiber, and polyphenols support beneficial microbiota and reduce pro-inflammatory bacterial taxa. Conversely, diets high in fat, red meat, and processed sugars promote microbial imbalance and increase cancer risk. Personalized nutrition plans based on an individual’s microbiome profile may offer more effective and sustainable cancer prevention strategies.

Beyond diet and supplementation, the microbiome also influences the efficacy of cancer therapies, including immunotherapies and chemotherapies. A balanced microbiota enhances immune responses, whereas dysbiosis can dampen the therapeutic effect and increase toxicity. Thus, preventive modulation of the microbiota may not only reduce cancer risk but also prime the body for better treatment outcomes if cancer does occur.

Despite its potential, microbiota-driven cancer prevention faces challenges. Interindividual variability, the complexity of host-microbe interactions, and the lack of standardized guidelines for intervention hinder clinical implementation. Furthermore, the long-term safety and efficacy of microbiota-targeted therapies require rigorous evaluation through large-scale clinical trials.

The future of this field lies in integrative approaches, combining genomic, microbial, dietary, and lifestyle data to develop precise and adaptable preventive strategies. Metagenomic sequencing, metabolomics, and machine learning are powerful tools that can help identify high-risk individuals, monitor intervention success, and refine preventive protocols.

Conclusion

Microbiota-driven cancer prevention represents a promising frontier in the global effort to reduce cancer incidence through biological modulation rather than reactive treatment. By targeting dysbiosis and enhancing microbial functions that support immune regulation, epithelial health, and anti-inflammatory responses, we can significantly lower oncogenic risk, particularly in gastrointestinal cancers. With continued research, microbiome-based interventions—ranging from diet to microbial therapeutics—may soon become integral to personalized prevention plans. As our understanding deepens, the microbiome is set to transform preventive oncology, making cancer risk management more proactive, precise, and sustainable.

References

1. Taquet M, Luciano S, Geddes JR, (2021). Lancet Psychiatry 8: 130-140.

   , ,

2. Kisely S, Sawyer E, Siskind D, Lalloo R (2016). J Affect Disord 200: 119-132.

   , ,

3. Elm EV, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. (2007). BMJ 335: 806-808.

   , ,

4. Tonetti MS, Prato GP, Cortellini P (1995). J Clin Periodontol 22: 229-234.

   , ,

5. Malinowska KS, Malicka B, Zi臋tek M, Zi臋tek M, Kaczmarek U, et al. (2018). Medicine (Baltimore) 97: e12490.

   , ,

6. Romanelli F, Adler DA, Bungay KM (1996). Ann Pharmacother 30: 1246-8.

   , ,

7. Hanawa T (2019). Front Bioeng Biotechnol 7: 170.

   , ,

8. Piqué EJ, Anglada M, RobledSM, Castaño JG, Echeverría F, et al. (2015). J Mater Sci Mater Med 26: 72.

   , ,

9. Pacheco KA (2019). Clin Rev Allergy Immunol 56: 72-85.

   , ,

10. Remes A, Williams DF (1992). Biomaterials 13: 731-743.

    , ,